BIIB Starts Felzartamab Phase III Study in AMR
Biogen (BIIB) announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase 3 study will evaluate the efficacy and ...
Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class ...
Biogen remains focused on advancing its immunology and rare disease pipeline, including three Phase 3 trials for Felzartamab in 2025. Q4 non-GAAP diluted EPS was $3.44 compared to analysts ...
Biogen Inc. (NASDAQ ... which includes Phase 3 trials for Felzartamab, a treatment for multiple myeloma and kidney diseases. Viehbacher commented, “So, you know, the race really that we are ...
Thanks, Jennifer, and good morning, and welcome to Biogen's fourth-quarter and full ... but I think we feel particularly excited about felzartamab and the potential this could have in rare kidney ...
Biogen's development organization had another ... is only the third agent with a positive global Phase III study in SLE. Additionally, Felzartamab was granted orphan drug designation in the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback